Clinical and psychological characteristics associated with negative beliefs and concerns about treatment necessity in rheumatic diseases.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 12 2022
30 12 2022
Historique:
received:
29
08
2022
accepted:
23
12
2022
entrez:
30
12
2022
pubmed:
31
12
2022
medline:
4
1
2023
Statut:
epublish
Résumé
Identifying factors that influence problematic beliefs and behaviors related to pharmacotherapy may be useful for clinicians to improve the patients' adherence. The study aims to assess patients' beliefs about the necessity and concerns regarding pharmacotherapy in rheumatic diseases and attitude styles, and to investigate the association between clinical factors and negative beliefs about medication. A sample of 712 patients affected by Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis was enrolled. They were assessed using the Beliefs about Medicines Questionnaires-Specific (BMQ), the Simplified Disease Activity Index (SDAI), the Visual Analogue Scale for pain (VAS), the Chalder Fatigue Scale (CFQ) and the Health Assessment Questionnaire-Disability Index (HAQ-DI). The balance between benefits and costs in the BMQ-Specific was positive in the 79.4% of patients, negative in the 12.1% and equal in the 8.6%. SDAI, taking more than 5 medications, taking anti interleukin 6 (Anti-IL6) or biological disease-modifying antirheumatic drugs (bDMARDs), or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), pain, and fatigue were significantly associated to higher Concerns. Having a longer disease duration was significantly associated with a higher Necessity, together with the current pharmacological treatments and the disability. The multivariate regression models estimated that higher pain and fatigue were associated to higher Concerns (p < 0.001), while a longer disease duration (p < 0.001) and all pharmacological treatments for a rheumatologic disease (p = 0.001) were associated to higher Necessity levels. A high length of disease, a low level of remission, a high number of total medications, the prescription of an Anti-IL6/bDMARDs/tsDMARDs drug, a high level of pain, fatigue and disability identified patients potentially less adherent to pharmacotherapy to be carefully looked after by clinicians.
Identifiants
pubmed: 36585438
doi: 10.1038/s41598-022-27046-5
pii: 10.1038/s41598-022-27046-5
pmc: PMC9803630
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22603Informations de copyright
© 2022. The Author(s).
Références
Rheumatol Int. 2012 Oct;32(10):3131-5
pubmed: 21947350
Rheumatology (Oxford). 2022 Aug 03;:
pubmed: 35920782
Rheumatol Int. 2010 Sep;30(11):1441-8
pubmed: 19823840
RMD Open. 2019 Jan 11;5(1):e000585
pubmed: 30713716
Adv Ther. 2017 Jan;34(1):91-108
pubmed: 27854054
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S14-8
pubmed: 16273780
Epidemiol Psichiatr Soc. 2010 Jan-Mar;19(1):86-92
pubmed: 20486428
Lupus. 2011 Jul;20(8):837-44
pubmed: 21511761
Rheumatology (Oxford). 2003 Feb;42(2):244-57
pubmed: 12595618
Curr Rheumatol Rev. 2020;16(3):215-223
pubmed: 31830886
PLoS One. 2013 Dec 02;8(12):e80633
pubmed: 24312488
Ann Rheum Dis. 2011 Jun;70(6):905-8
pubmed: 21540200
Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288
pubmed: 31823381
Rheumatology (Oxford). 2005 Jun;44(6):762-7
pubmed: 15741193
Medicina (Kaunas). 2020 Apr 14;56(4):
pubmed: 32295226
Ther Innov Regul Sci. 2013 May;47(3):341-348
pubmed: 30231436
Rheumatology (Oxford). 2004 May;43(5):583-6
pubmed: 14970399
Acta Derm Venereol. 2019 Apr 1;99(4):386-392
pubmed: 30543381
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
J Psychosom Res. 1999 Dec;47(6):555-67
pubmed: 10661603
Ann Rheum Dis. 1978 Aug;37(4):382-4
pubmed: 308355
Rheumatology (Oxford). 2020 Jan 1;59(1):213-223
pubmed: 31302692
J Rheumatol. 2003 Nov;30(11):2469-75
pubmed: 14677194
Adv Rheumatol. 2021 Sep 15;61(1):57
pubmed: 34526144
Semin Arthritis Rheum. 2013 Aug;43(1):18-28
pubmed: 23352247
Rheumatology (Oxford). 2004 Jul;43(7):901-5
pubmed: 15113996
J Psychosom Res. 2008 Jan;64(1):47-54
pubmed: 18157999
Am J Med Sci. 2010 Oct;340(4):282-90
pubmed: 20881757
Chronic Illn. 2009 Jun;5(2):129-33
pubmed: 19474235
Inflamm Bowel Dis. 2009 Jun;15(6):837-44
pubmed: 19107771
Patient Prefer Adherence. 2018 Jun 22;12:1099-1111
pubmed: 29970960
Patient Prefer Adherence. 2018 Jul 03;12:1151-1166
pubmed: 30013327
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991
Patient Prefer Adherence. 2014 Nov 25;8:1635-45
pubmed: 25525340
Innov Pharm. 2021 Jan 13;12(1):
pubmed: 34007676
Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi5-9
pubmed: 23221588